Zentalis Pharmaceuticals, Inc. Capital Expenditures Incurred but Not yet Paid
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Cash Flow
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2024-02-27
- Zentalis Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for the quarter ending 2023-06-30 was -$209.00K.
- Zentalis Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for the quarter ending 2023-03-31 was $209.00K, a 7.52% decline year-over-year.
- Zentalis Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-06-30 was -$135.00K.
- Zentalis Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for the quarter ending 2022-03-31 was $226.00K, a 237.31% increase year-over-year.
- Zentalis Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $0.00.
- Zentalis Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Zentalis Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for fiscal 2021 was $1.51M.
- Zentalis Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for fiscal 2020 was $0.00.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-27 | ||
| 2023-06-30 | -$209.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $209.00K 10-Q · filed 2023-05-10 | ||
| 2022-12-31 | $0.00 10-K · filed 2024-02-27 | ||
| 2022-06-30 | -$135.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $91.00K 10-Q · filed 2023-08-09 | |
| 2022-03-31 | $226.00K 10-Q · filed 2023-05-10 | ||
| 2021-12-31 | $1.51M 10-K · filed 2024-02-27 | ||
| 2021-06-30 | -$67.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | |
| 2021-03-31 | $67.00K 10-Q · filed 2022-05-05 | ||
| 2020-12-31 | $0.00 10-K · filed 2023-03-01 | ||
| 2020-03-31 | $25.00K 10-Q · filed 2021-05-17 | ||
| 2019-12-31 | $0.00 10-K · filed 2022-02-24 | ||
| 2019-03-31 | $7.00K 10-Q · filed 2020-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |